AnaptysBio Inc. (ANAB)
AnaptysBio Inc. (ANAB) Stock Price, Analysis & Data
| Bid | 41.67 |
| Market Cap | 1.69B |
| Revenue (ttm) | 232.39M |
| Net Income (ttm) | -26.79M |
| Beta | 0.40 |
| EPS (ttm) | -1 |
| PE Ratio (ttm) | n/a |
| Forward PE | 10.88 |
| P/B (ttm) | 129.79 |
| P/S (ttm) | 7.26 |
| Earnings Date | Aug 13, 2026 |
| Ask | 73.4 |
| Volume | 375,099 |
| Avg. Volume (20D) | 634,643 |
| Open | 57.99 |
| Previous Close | 57.87 |
| Day's Range | 56.65 - 58.11 |
| 52-Week Range | 11.40 - 72.36 |
| Analyst | Strong Buy |
| Price Target | 81 (42.16%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ANAB
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; A...
Financial Performance
In 2025, AnaptysBio's revenue was 234.6M, an increase of 157.01% compared to the previous year's 91.28M. Earnings were -13.23M, a decrease of -90.89%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for ANAB stock is "Strong Buy". The 12-month stock price forecast is 81, which is upside of 42.16% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
